1. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-2139. doi:10.1016/S0140-6736(02)09088-8
2. Matikas A, Foukakis T, Bergh J. Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. Crit Rev Oncol Hematol. 2017;114:91-101. doi:10.1016/j.critrevonc.2017.04.002
3. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000;2(2):86-90. doi:10.1186/bcr38
4. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109(9):1139-1142. doi:10.1172/jci15617
5. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-3444. doi:10.1200/JCO.2008.18.9068
6. Villaseñor A, Flatt SW, Marinac C, Natarajan L, Pierce JP, Patterson RE. Postdiagnosis c-reactive protein and breast cancer survivorship: Findings from the WHEL study. Cancer Epidemiol Biomarkers Prev. 2014;23(1):189-199. doi:10.1158/1055-9965.EPI-13-0852
7. McAndrew NP, Bottalico L, Mesaros C, et al. Effects of systemic inflammation on relapse in early breast cancer. npj Breast Cancer. 2021;7(1). doi:10.1038/s41523-020-00212-6
8. DeMichele A, Gray R, Horn M, et al. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009;69(10):4184-4191. doi:10.1158/0008-5472.CAN-08-2989
9. Dethlefsen C, Højfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657-664. doi:10.1007/s10549-013-2488-z
10. Ham M, Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression. Arch Pharm Res. 2013;36(12):1419-1431. doi:10.1007/s12272-013-0271-7
11. Sansone P, Ceccarelli C, Berishaj M, et al. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun. 2016;7. doi:10.1038/NCOMMS10442
12. Siersbæk R, Scabia V, Nagarajan S, et al. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. Cancer Cell. 2020;38(3):412-423.e9. doi:10.1016/J.CCELL.2020.06.007
13. Bromberg J, Wang TC. Inflammation and Cancer: IL-6 and STAT3 Complete the Link. Cancer Cell. 2009;15(2):79-80. doi:10.1016/j.ccr.2009.01.009
14. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117. doi:10.1182/blood-2009-04-214957
15. Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: What is next? Blood. 2017;130(2):115-125. doi:10.1182/blood-2017-04-742288
16. Stover DG, Gil Del Alcazar CR, Brock J, et al. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. npj Breast Cancer. 2018;4(1):10. doi:10.1038/s41523-018-0060-z
17. O’Shaughnessy J, DeMichele A, Ma CX, et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat. 2018;170(3):547-557. doi:10.1007/s10549-018-4770-6
18. Lynce F, Williams JT, Regan MM, et al. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021;87(5):673-679. doi:10.1007/S00280-021-04245-X/TABLES/4
19. Kearney M, Franks L, Lee S, et al. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Res Treat. 2021;189(1):177-185. doi:10.1007/S10549-021-06306-4/FIGURES/3
20. Buzdar AU, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95(9):2006-2016. doi:10.1002/cncr.10908
21. Jones SA, Jones SE. Exemestane: a novel aromatase inactivator for breast cancer. Clin Breast Cancer. 2000;1(3):211-216. doi:10.3816/CBC.2000.n.017
22. Lonning PE. Pharmacology and clinical experience with exemestane. Expert Opin Investig Drugs. 2000;9(8):1897-1905. doi:10.1517/13543784.9.8.1897
23. Lønning PE. Exemestane: A review of its clinical efficacy and safety. Breast. 2001;10(3):198-208. doi:10.1054/brst.2001.0293
24. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14(9):1391-1398. doi:10.1093/annonc/mdg362
25. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Rsults from EFECT. J Clin Oncol. 2008;26(10):1664-1670. doi:10.1200/JCO.2007.13.5822
26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10. doi:10.1016/0197-2456(89)90015-9
27. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol. 2006;34(9):1182-1190. doi:10.1016/j.exphem.2006.05.002
28. AMM F, DF C, G N, et al. Derivatization of estrogens enhances specificity and sensitivity of analysis of human plasma and serum by liquid chromatography tandem mass spectrometry. Talanta. 2016;151:148-156. doi:10.1016/J.TALANTA.2015.12.062
29. Kalota A, Jeschke GR, Carroll M, Hexner EO. Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis. Clin Cancer Res. 2013;19(7). doi:10.1158/1078-0432.CCR-12-1907
30. Bidard F-C, Callens C, Pistilli B, et al. Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial. Ann Oncol. 2019;30:v105-v106. doi:10.1093/ANNONC/MDZ242.002
31. Stoenescu A, Gerlinger C, Solomayer EF, Scholz C, Juhasz-Böss I, Radosa J. Serum C-Reactive Protein as Potential Independent Prognostic Factor for Breast Cancer. Vol 27.; 2015.
32. Hartman ZC, Yang X-Y, Glass O, et al. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res. 2011;71(13):4380-4391. doi:10.1158/0008-5472.CAN-11-0308
33. Singh A, Purohit A, Duncan LJ, Mokbel ~ K, Ghilchik MW, Reed MJ. Control of Aromatase Activity in Breast Tumours: The Role of the Immune System. Vol 61.; 1997.
34. Purohit A, Ghilchik MW, Duncan L, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab. 1995;80(10):3052-3058. doi:10.1210/jcem.80.10.7559896
35. Woo P, Humphries SE. IL-6 polymorphisms: A useful genetic tool for inflammation research? J Clin Invest. 2013;123(4):1413-1414. doi:10.1172/JCI67221
36. Lorente L, Martín MM, Pérez-Cejas A, et al. Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients. Int J Mol Sci. 2016;17(11). doi:10.3390/IJMS17111861